Phase 2: testing Nivolumab for Cancer
Main Objective of this study is to examine long-term safety of nivolumab this drug alone including combinations and other cancer therapies in various tumor types.
Official registry: https://clinicaltrials.gov/study/NCT03899155 · Bristol-Myers Squibb · enrollment listed as 1,500
What this phase means
Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Nivolumab, Ipilimumab, or Cabozantinib. The registry lists allocation as randomized. Main Objective of this study is to examine long-term safety of nivolumab this drug alone including combinations and other cancer therapies in various tumor types.
They plan to enroll about 1,500 people at 407 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.
Official title (unrewritten)
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
Interventions: Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab, Nivolumab + Relatlimab, Capecitabine, Bevacizumab, Temozolomide, Rucaparib, Daratumumab, Regorafinib, Leucovorin, Fluorouracil, Oxaliplatin, Enzalutamide, Sunitinib, Pemetrexed, Pembrolizumab
Primary outcome (registry wording): Incidence of Adverse Events (AEs)
Who it is for (from inclusion criteria)
- Ages 18 Years to any
- Eligible to receive continued study treatment per the Parent Study, including treatment beyond progression per investigator assessment in the Parent Study
- On treatment hold in the Parent Study following long-lasting response or are eligible for treatment rechallenge as defined in the Parent Study
- WOCBP and male participants who are sexually active must agree to follow instructions for method(s) of contraception as described below and included in the ICF
Who the registry excludes
- Participant is not eligible for study treatment per the Parent Study eligibility criteria
- Participants not receiving clinical benefit as assessed by the Investigator
- Any clinical adverse event (AE), laboratory abnormality, or intercurrent illness which, in the opinion of the Investigator, indicates that participation in the study is not in the best interest of the participant
- Other protocol-defined Inclusion/
Public study contact (from the registry)
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
407 listed- Local Institution - 0220 — Huntsville, Alabama (completed)
- University of Arizona College of Medicine — Tucson, Arizona (withdrawn)
- Innovative Clinical Research Institute — Lynwood, California (withdrawn)
- Local Institution — San Francisco, California (withdrawn)
- Local Institution - 0099 — San Francisco, California (completed)
- Local Institution - 0233 — Aurora, Colorado (completed)
- Local Institution - 0095 — New Haven, Connecticut (withdrawn)
- Local Institution - 0088 — Washington D.C., District of Columbia (completed)
- Florida Cancer Affiliates — Ocala, Florida (withdrawn)
- Local Institution — Orlando, Florida (withdrawn)
- Local Institution - 0024 — Tampa, Florida (completed)
- Local Institution - 0105 — Chicago, Illinois (completed)
+ 349 sites outside the US on the same record
FAQ about this NCT record
Is NCT03899155 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT03899155?
Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT03899155?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary